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AbstrAct
Objective to validate the canada-Denmark (canDen) Mri 
scoring system for the spine in axial spondyloarthritis with 
updated lesion definitions.
Methods lesion definitions in the canDen system were 
updated and illustrated by a consensus set of reference 
images. Sagittal spine Mris of 40 patients with axial 
spondyloarthritis obtained at baseline and at week 52 
after initiation of treatment with the tumour necrosis 
factor inhibitor golimumab were evaluated in unknown 
chronology by seven readers blinded to all other data.
Results canDen Mri spine inflammation score had very 
good reliability for status scores (single-measure intraclass 
correlation coefficient (icc) of 21 reader pairs median of 
0.91 (iQr 0.88–0.92)) and change scores (icc 0.88 (0.86–
0.92)). canDen Mri spine fat score had good to very good 
reliability for status scores (icc 0.79 (0.75–0.86)) and 
moderate to good reliability for detecting change (icc 0.59 
(0.46–0.73)). canDen Mri spine bone erosion score and 
canDen Mri spine new bone formation score had slight to 
moderate reliability for status scores (icc 0.38 (0.32–0.52) 
and 0.39 (0.27–0.49), respectively).
Conclusion the canDen Mri spine scoring system 
allows a comprehensive evaluation of inflammation, fat, 
bone erosion and new bone formation of the spine in 
patients with axial spondyloarthritis. it demonstrated very 
good reliability for detecting change in inflammation, 
moderate to good reliability for detecting change in fat, and 
slight to moderate reliability for detecting bone erosions 
and new bone formation. Studies with longer follow-up or 
patients with more advanced spinal involvement may be 
needed to reliably detect change in bone erosion and new 
bone formation scores.
Trial registration number nct02011386.
InTROduCTIOn
In 2009, the Canada-Denmark (CANDEN) 
MRI working group published definitions 
of pathologies, an atlas of inflammatory and 
structural lesions of the spine, and the relia-
bility for scoring various lesions among the 
founders of the system (RGWL, WM, SJP and 
MØ).1–5 Later, preliminary CANDEN MRI 
spine scores of inflammation, fat lesion, bone 
erosion and new bone formation were devel-
oped based on these lesion definitions, and 
they were applied in two studies of patients 
with axial spondyloarthritis (axSpA) and 
ankylosing spondylitis (AS) treated with 
tumour necrosis factor (TNF) inhibitor,6–8 
where significant changes in the scores over 
Key messages
What is already known about this subject?
 ► the canada-Denmark (canDen) scoring system is 
a comprehensive scoring system that allows eval-
uation of inflammatory and structural lesions of the 
spine in patients with axial spondyloarthritis.
What does this study add?
 ► in a multireader setting with experienced as well as 
newly trained Mri readers, the canDen Mri spine 
scoring system demonstrated very good reliability 
for detecting change in inflammation, moderate to 
good reliability for detecting change in fat, and slight 
to moderate reliability for detecting bone erosions 
and new bone formation.
 ► Four inflammation subscores that capture different 
anatomical parts of the spine were developed.
How might this impact on clinical practice?
 ► the scoring system can be used to investigate how 
drugs with different modes of action influence the 
individual components of spine inflammation and 
damage, the mutual relationship between lesions, as 
well as the evolution of inflammation and damage in 
the entire spine.
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Table 1 MRI lesion definitions
Normal bone marrow 
signal
The bone marrow signal in the centre of the vertebral body, if normal, constitutes the reference for 
designation of normal signal. If the usual reference point is not normal, then the closest vertebra with 
normal marrow signal in the centre of the vertebral body is used as reference.
Central vs lateral 
slices
Definitions of central and lateral slices: Central sagittal slices (referred to as central slices) are slices 
that include the spinal canal. The pedicle may be partially seen but is not continuous between the 
vertebral body and the posterior elements. Lateral sagittal slices (referred to as lateral slices) are slices 
that do not include the spinal canal and where the pedicle is continuous between the vertebral body 
and the posterior elements, or the slice is lateral to the pedicle. Vertebral body inflammatory lesions 
and fat lesions are scored on central and lateral slices. Vertebral body bone erosion and new bone 
formation are scored on central slices only.
Reference point for slice position: The slice position is defined by the discovertebral unit (DVU) and 
not by the vertebral body. Therefore, the slice position will always be the same for both endplates of a 
DVU. The reference structure is the pedicle related to the lower endplate of the DVU. For example, the 
slice position of both endplates at L1/L2 is defined by the presence/absence of the L2 pedicle on that 
image.
Reference sequence: Whether T1-weighted (T1W) or short tau inversion recovery (STIR) is used 
to designate slice position will depend on the lesion domain that is being evaluated, that is, for fat 
lesions, bone erosion and new bone formation this would be the T1W sequence, and for inflammatory 
lesions this would be the STIR sequence.
Slices in the cervical 
spine
In the cervical spine, facet joints are located laterally to the vertebral body and are not seen on the 
same sagittal image. Therefore, in the cervical spine, all images that include the vertebral body are 
defined as central slices. For C7/T1, C7 is scored as a cervical vertebra while T1 is scored as a 
thoracic vertebra.
Inflammatory lesion Inflammatory lesion in vertebral bodies: Increased signal in bone marrow on STIR/T2FS in a vertebral 
body.
Corner inflammatory lesion (CIL), subdivided into anterior (aCIL) and posterior (pCIL): Inflammatory 
lesion at the vertebral corner on at least one central slice.
Type A CIL: The inflammatory lesion itself reaches the corner.
Type B CIL: The inflammatory lesion does not extend to the corner but does extend to both the 
vertebral endplate and the anterior/posterior vertebral cortex (usually because of the presence of fat or 
erosion in the corner). If a type B CIL is present, a type A CIL cannot be scored.
Non-corner inflammatory lesion (NIL): Inflammatory lesion adjacent to the endplate on a central slice 
but not involving the anterior or posterior vertebral corner.
Lateral vertebral body inflammatory lesion (LIL), subdivided into anterolateral (aLIL) and posterolateral 
(pLIL): Inflammatory lesion adjacent to the endplate on a lateral slice without distinction between 
corner and non-corner lesions.
Inflammatory lesions involving the posterior elements of the spine, not the vertebral bodies:
Facet joint inflammatory lesion: Increased signal in bone marrow on STIR/T2FS in at least one facet of 
a facet joint.
Transverse process inflammatory lesion: Increased signal in bone marrow on STIR/T2FS in the 
transverse process.
Rib inflammatory lesion: Increased signal in bone marrow on STIR/T2FS in the rib.
Spinous process inflammatory lesion: Increased signal in bone marrow on STIR/T2FS in the spinous 
process.
Soft tissue inflammatory lesion: Increased signal in soft tissue at entheseal attachments on STIR/T2FS.
Continued
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Fat lesion Focally increased signal in bone marrow on T1W.
Corner fat lesion (CFAT), subdivided into anterior (aCFAT) and posterior corner fat lesion (pCFAT): Fat 
lesion at the vertebral corner on at least one central slice.
Non-corner fat lesion (NFAT): Fat lesion adjacent to the endplate on any central slice but not involving 
the anterior or posterior vertebral corner.
Lateral vertebral body fat lesion (LFAT), subdivided into anterolateral (aLFAT) and posterolateral 
vertebral body fat lesion (pLFAT): Fat lesion adjacent to the endplate on a lateral slice without 
distinction between corner and non-corner lesions.
Facet joint fat lesion: Increased signal in bone marrow on T1W in at least one facet of a facet joint.
Fat lesions in the upper cervical spine: To be considered a true fat lesion in the upper part of the 
cervical spine, a potential lesion has to be very homogeneous and to have a clearly increased signal 
on T1W that is clearly demarcated from adjacent bone marrow. This applies especially for C2 and C3 
lower anterior corners, where a diffuse signal increase on T1W is common in healthy subjects. It may 
be necessary to use different windowing of the image for optimal visualisation of the upper vs the 
lower cervical spine.
Bone erosion Full-thickness loss of dark appearance of cortical bone at its anticipated location and loss of normal 
bright appearance of adjacent bone marrow on T1W. Vertebral bone erosions are scored on central 
slices only.
Corner bone erosion, subdivided into anterior and posterior corner erosion: Bone erosion involving the 
vertebral corner on a central slice.
Facet joint bone erosion: Bone erosion involving at least one facet of a facet joint.
New bone formation Because of the current limitations of MRI, the following definitions are restricted to only those bone 
spurs within which bone marrow signal is detectable. In the future, MRI may be able to detect 
mineralisation within the bone spur at an earlier stage.
Bone spur: Bright signal on T1W extending from the vertebral endplate towards the adjacent vertebra.
Corner bone spur (syndesmophyte) (COS), subdivided into anterior (aCOS) and posterior corner bone 
spur (pCOS): Bone spur at the vertebral corner on a central slice.
Non-corner bone spur: Bone spur involving the endplate, which involves neither the anterior nor the 
posterior vertebral corner on a central slice.
Ankylosis: Bright signal on T1W extending from a vertebra and being continuous with the adjacent 
vertebra.
Corner ankylosis, subdivided into anterior and posterior corner ankylosis: Ankylosis at the anterior or 
posterior corner on a central slice.
Non-corner ankylosis: Ankylosis which involves the endplate, but neither the anterior nor the posterior 
vertebral corner on a central slice.
Facet joint ankylosis: Ankylosis at the facet joint.
Assessment of size 
of inflammatory 
lesion/fat lesion/bone 
erosion
Size is only assessed for lesions on central slices in the thoracic and lumbar spine; the slice where 
the lesion is largest is used. Size of corner lesions is assessed vertically perpendicular to the vertebral 
endplate and horizontally parallel to the vertebral endplate. Corner lesions are large if they involve 25% 
or more of the anterior-posterior diameter of the vertebral endplate and/or the height of the vertebral 
body. Non-corner lesions are large if they involve more than 25% of the vertebral body height. If either 
new bone formation or bone erosion is distorting the configuration of the corner, size is measured from 
the point at which the original cortex and endplate would have met. Inflammatory lesions, fat lesions 
and bone erosions are assessed for size.
Combined corner 
and non-corner 
inflammatory lesion/
fat lesion
If a corner inflammatory lesion/fat lesion on any central slice involves more than 50% of the 
anteroposterior diameter of the vertebra (ie, it extends beyond the midpoint), it is scored as both 
a corner inflammatory lesion/fat lesion and a non-corner inflammatory lesion/fat lesion. Size of the 
corner component can only be assessed by vertical extent at the anterior/posterior vertebral cortex 
(horizontal size cannot be assessed). Size of the non-corner component is assessed by height at the 
midpoint of the anteroposterior diameter of the vertebra.
Combined central 
slice and lateral slice 
inflammatory lesion/
fat lesion
An inflammatory lesion/fat lesion may be observed extending across both central and lateral slices. It 
is then scored as being both a central (aCIL/pCIL/NIL) and lateral (aLIL/pLIL) inflammatory lesion, or a 
central (aCFAT/pCFAT/NFAT) and lateral (aLFAT/pLFAT) fat lesion.
T2FS, T2-weigted image with fat saturation.
Table 1 Continued
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1–5 years occurred, except for bone erosion. These 
results suggest that the CANDEN MRI spine scoring 
system allows a comprehensive, anatomy-based evalu-
ation of both inflammatory and structural lesions, and 
that it can provide patient-level sum scores for inflam-
matory lesions, fat lesions, bone erosion and new bone 
formation that are responsive to detect change.
Several other MRI scoring systems of the spine have 
been developed. The Ankylosing Spondylitis spine 
Magnetic Resonance Imaging (ASspiMRI) method 
provides an activity score of 0–6 and a chronicity score 
of 0–6 for each discovertebral unit (DVU).9 10 The Berlin 
method provides an activity score of 0–3 per DVU and was 
later amended to allow assessment of inflammation of the 
posterior segments with a score of 0–2, and erosions, fatty 
bone marrow deposition and bone proliferation, each 
with a score of 0–3 per DVU.11–16 The Spondyloarthritis 
Research Consortium of Canada (SPARCC) MRI Spine 
Inflammation Index divides each DVU into four verte-
bral quadrants, which are assessed for presence/absence 
of bone marrow oedema with additional scores for inten-
sity and depth. This is done on three consecutive slices, 
and provides a score of 0–18 for each DVU and has been 
used for scoring either the 6 worst affected DVUs or all 23 
DVUs.17–21 Assessment of inflammation in pedicles, facet 
joints, transverse processes, spinous processes and soft 
tissues in relation to the SPARCC method has been investi-
gated.22 The Leeds method counts the number of inflam-
matory lesions in the vertebral bodies, spinous processes, 
facet joints and soft tissue in the lumbar spine.23 24 The 
Aarhus method provides an activity score of 0–3, and an 
additional score of 1 for costovertebral involvement for 
each DVU and a chronicity score of 0–9 for each DVU.25 
The ASspiMRI, Berlin and SPARCC scoring methods for 
inflammatory activity were compared in a multireader 
study.26
The CANDEN MRI spine scoring system is a compre-
hensive system which permits a detailed description of 
the involvement of different spinal structures, various 
topographic parts of the vertebral bodies, the facet 
joints, the spinous processes, the transverse processes, 
the ribs and soft tissue. By covering various inflamma-
tory and structural lesion types, the CANDEN MRI spine 
scoring system may help identify subgroups of patients 
and different disease trajectories. It also allows investiga-
tion of the relation between different lesion types over 
time at the lesion level and at the patient level,27–29 and 
how this association may vary depending on the mode 
of action of the applied therapy. In this updated version 
of the scoring system, we have harmonised the defini-
tions and rules across the various lesion types in order to 
ease the use of the system. Sum scores for inflammation, 
fat and erosion differ slightly from the preliminary sum 
scores that were previously published,6–8 but differences 
are minor; the decision to make this update of the system 
was driven by a desire for internally consistent rules, defi-
nitions and accompanying atlas.
The objective of this work was to update the lesion 
definitions including an atlas with consensus reference 
images, clarify the CANDEN MRI spine scoring system 
for inflammation and structural lesions, and assess the 
reliability of the scoring system in a multireader setting.
MeTHOds
Patient characteristics
Sagittal MRIs of the spine of 40 patients with axSpA 
obtained at baseline and after 52 weeks in the MANGO 
(Novel MRI ANd biomarkers in GOlimumab-treated 
patients with axial spondyloarthritis) cohort study ( Clin-
icalTrials. gov: NCT02011386) were used. All patients 
were diagnosed with axSpA and fulfilled the imaging 
arm of the Assessment of SpondyloArthritis international 
Society (ASAS) axSpA criteria. TNF inhibitor treatment 
with golimumab 50 mg once every month was initiated in 
all patients at baseline. The median age of the 40 patients 
was 33 years (IQR 28–48, range 22–73), 55% were men, 
73% were human leucocyte antigen B27 (HLA-B27)-posi-
tive, 24 (60%) fulfilled the radiographic part of the modi-
fied New York criteria, while 16 (40%) had non-radio-
graphic axSpA, with a median time since diagnosis of 0.7 
years (IQR 0.2–3.4) and median symptom duration of 4.6 
years (IQR 2.1–9.8). At baseline, 53% had elevated C-re-
active protein (CRP) (defined as >5 mg/L), Ankylosing 
Spondylitis Disease Activity Score (ASDAS) median of 3.6 
(IQR 3.1–4.0) and SPARCC sacroiliac joint (SIJ) inflam-
mation median score of 14 (IQR 8–22). At week 52, 21% 
had elevated CRP, ASDAS median of 1.4 (IQR 0.8–2.2) 
and SPARCC SIJ inflammation median score of 2 (IQR 
0–4).
MRI methodology
MRI of the spine was performed at baseline and at week 
52. Spine images were acquired in two halves (upper 
and lower spine). MRI was performed on a single high-
field Philips Medical Systems Ingenia scanner (3.0 T) 
by sagittal T1-weighted turbo spin echo: repetition time 
(TR): 663 ms, echo time (TE): 8 ms, matrix: 444×319, 
field of view (FOV): 400×180 mm, slice thickness 4 mm, 
interslice gap 0.4 mm, and acquisition duration for 
upper/lower spine: 2 min 7 s each; and by short tau inver-
sion recovery: TR: 3476 ms, TE: 70 ms, inversion time: 
210 ms, matrix: 400×307/400×307, FOV: 400×180 mm, 
slice thickness 4 mm, interslice gap 0.4 mm, and acqui-
sition duration for upper/lower spine: 5 min 23 s each.
Two readers screened the images for variation in spinal 
segmentation using C2 as the reference vertebra. Four 
patients had partial or complete sacralisation of L5 or 
lumbarisation of S1. In case of lumbarisation of S1, the 
DVU between S1 and S2 was not scored. Images were 
read independently by seven readers, of whom five were 
experienced readers (MØ, SJP, UW, WM and RGWL) and 
two were newly trained readers with less experience (SK 
and GK). This was done without knowledge of clinical, 
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Table 2 Scoring rules
CANDEN MRI spine 
inflammation score
The following lesions are scored as 0 (absent) or 1 (present): aCIL, pCIL, NIL, aLIL, pLIL, FIL, TIL, RIL, 
SPIL and STIL. A score of 1 is added for large aCIL and pCIL. Non-corner lesions (NIL) are scored as 0 
(absent) or 2 (present), and a score of 2 is added for large non-corner lesions (NIL).
The CANDEN MRI spine inflammation score has a total scoring range of 0–614. The vertebral body 
subscore has a score range of 0–464 (11 cervical endplates from C2 to C7, each with a maximum 
score of 4, 35 thoracic/lumbar endplates from T1 to S1 each with a maximum score of 12). The 
posterior elements subscore has a score range of 0–150 (facet joints at all 23 levels from C2/C3 to L5/
S1, transverse process at 17 levels from T1 to L5, rib at 12 levels from T1 to T12, spinous process at 
23 levels from C2 to L5, soft tissue inflammation at 23 levels from C2/C3 to L5/S1).
The CANDEN MRI spine inflammation score may also be divided into the following four subscores:
 ► A, ‘Vertebral body corner inflammation subscore’, defined as the sum of the anterior and posterior 
corner lesions, and anterolateral and posterolateral vertebral body lesions (posterolateral vertebral 
body lesions only at levels T12/L1 to L5/S1), which may predominantly represent enthesitis related 
to the anterior and posterior longitudinal ligament and the annulus fibrosus (range 0–254).
 ► B, ‘Spondylodiscitis subscore’, defined as the sum of non-corner vertebral body lesions, which may 
predominantly represent inflammation from the disc or endplate itself (range 0–162).
 ► C, ‘Facet joint inflammation subscore’, defined as the sum of facet joint lesions, representing 
inflammation of the synovial facet joints (range 0–46).
 ► D, ‘Posterolateral elements inflammation subscore’, defined as the sum of rib, transverse process, 
spinous process, soft tissue inflammation and posterolateral vertebral body lesions (posterolateral 
vertebral body only at levels C7/T1 to T11/T12 because pLIL in the thoracic spine is considered to 
be related to the costovertebral joint), representing inflammation related to these synovial joints and 
enthesitis of ligaments of the posterior elements of the spine (range 0–152).
CANDEN MRI spine 
fat score
The following lesions are scored as 0 (absent) or 1 (present): aCFAT, pCFAT, aLFAT, pLFAT and FFAT. A 
score of 1 is added for large aCFAT and pCFAT. Non-corner lesions (NFAT) are scored as 0 (absent) or 
2 (present), and a score of 2 is added for large non-corner lesions (NFAT).
The total scoring range for the CANDEN MRI spine fat score is 0–510. The range for the vertebral 
body subscore is 0–464 (11 cervical endplates each with a maximum score of 4, 35 thoracic/lumbar 
endplates each with a maximum score of 12). The range for the fat posterior elements subscore is 
0–46 (facet joints at all 23 levels).
CANDEN MRI spine 
bone erosion score
The following lesions are scored as 0 (absent) or 1 (present): aCOBE, pCOBE and FABE. A score of 1 
is added for large aCOBE and pCOBE.
The total scoring range for the CANDEN MRI spine bone erosion score is 0–208. The range for the 
vertebral body subscore is 0–162 (11 cervical endplates each with a maximum score of 2, 35 thoracic/
lumbar endplates each with a maximum score of 4). The range for the posterior elements subscore is 
0–46 (facet joints at all 23 levels).
CANDEN MRI spine 
new bone formation 
score
Anterior corner, posterior corner and non-corner ankylosis are scored as 0 (absent) or 6 (present). 
Anterior corner, posterior corner and non-corner bone spurs are scored as 0 (absent) or 2 (present). 
Facet joint ankylosis is scored as 0 (absent) or 1 (present).
The total scoring range for the CANDEN MRI spine new bone formation score is 0–460. The range 
for the vertebral body subscore is 0–414 (23 levels with a maximum score of 18). The range for the 
posterior elements subscore is 0–46 (facet joints at all 23 levels).
aCFAT, anterior corner fat lesion; aCIL, anterior corner inflammatory lesion; aCOBE, anterior corner bone erosion; aLFAT, anterolateral 
vertebral body fat lesion; aLIL, anterolateral vertebral body inflammatory lesion; CANDEN, Canada-Denmark; FABE, facet joint bone erosion; 
FFAT, facet joint fat lesion; FIL, facet joint inflammatory lesion; NFAT, non-corner fat lesion; NIL, non-corner inflammatory lesion; pCFAT, 
posterior corner fat lesion; pCIL, posterior corner inflammatory lesion; pCOBE, posterior corner bone erosion; pLFAT, posterolateral vertebral 
body fat lesion; pLIL, posterolateral vertebral body inflammatory lesion; RIL, rib inflammatory lesion; SPIL, spinous process inflammatory 
lesion; STIL, soft tissue inflammatory lesion; TIL, transverse process inflammatory lesion.
biochemical and other imaging information and blinded 
to chronology.
description of the CAnden scoring system
Lesion definitions applied in the CANDEN MRI spine 
scoring system are provided in table 1, and all the rules for 
scoring lesions and calculating the CANDEN patient-level 
scores and subscores are provided in table 2. To improve 
the use of the system, the original set of reference images 
for all four lesion types (inflammatory lesions, fat lesions, 
bone erosion and new bone formation) with definitions 
of lesions, rules for scoring, and examples of lesions 
above and below the threshold for scoring were updated 
and made available at www. carearthritis. com and www. 
copecare. dk
statistical analysis
Patient-level sum scores for each lesion type (inflam-
matory lesions, fat lesions, bone erosion and new bone 
formation) were calculated based on each reader’s 
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scores. The reliability of patient-level sum scores was 
assessed by pairwise intraclass correlation coefficients 
(ICC) for status scores and for change scores between 
all reader pairs, based on two-way single-measure models 
by absolute agreement and two-way average-measure 
models by absolute agreement. Similar analyses were also 
performed separately for the vertebral bodies and poste-
rior elements, as well as for all individual components. 
Agreement plots in which a reader’s scores are plotted 
against the mean score of all readers allow a graphical 
assessment of the agreement between multiple readers. 
The reliability at the lesion level was assessed for status 
scores and change scores between all reader pairs by pair-
wise kappa with squared weights. Kappa values and ICC 
values ≥0.8 were considered to represent very good reli-
ability, ≥0.6 to <0.8 good reliability, ≥0.4 to <0.6 moderate 
reliability, ≥0.2 to <0.4 slight reliability, and <0.2 poor reli-
ability.
The responsiveness for changes in CANDEN MRI 
spine inflammation score, CANDEN MRI spine fat score, 
CANDEN MRI spine bone erosion score and CANDEN 
MRI spine new bone formation score between baseline 
and week 52 was assessed based on the observed status 
and change scores. Change at group level was tested for 
statistical significance using Wilcoxon signed-rank test.
ResulTs
The CANDEN MRI spine inflammation score and all 
its subscores decreased significantly, the CANDEN 
MRI spine fat score increased significantly, whereas 
the CANDEN MRI spine bone erosion score and the 
CANDEN MRI spine new bone formation score remained 
largely unchanged (see table 3).
The reliability of the CANDEN MRI spine inflamma-
tion score was good to very good, and the reliability of 
the CANDEN MRI spine fat score was moderate to very 
good, for status scores and change scores during active 
treatment after 52 weeks of follow-up (see figure 1). The 
reliability of the CANDEN MRI spine bone erosion score 
and the CANDEN MRI spine new bone formation score 
was slight to moderate for status scores.
All readers had a largely similar mean CANDEN MRI 
spine inflammation score and CANDEN MRI spine fat 
score, both regarding baseline score and decrease in 
score during follow-up. Most readers identified no overall 
change in CANDEN MRI spine bone erosion score or 
CANDEN MRI spine new bone formation score during 
follow-up. Differences between readers’ scores tended to 
be smaller for patients with small mean scores and larger 
for patients with large mean scores for all four lesion 
types (see online supplementary figure 1 and online 
supplementary table 1).
Almost all components of the CANDEN MRI spine 
inflammation score, that is, anterior corner, posterior 
corner, non-corner, anterolateral, posterolateral, trans-
verse process, rib, facet joint and soft tissue inflamma-
tory lesions, decreased significantly during the 52-week 
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Figure 1 Inter-reader reliability, single-measure intraclass correlation coefficient (ICC) values for agreement at the patient level 
in pairwise combinations of readers.
follow-up. Spinous process inflammation also tended to 
decrease, although this did not reach statistical signifi-
cance (see online supplementary table 2).
Similarly, for the CANDEN MRI spine fat score, anterior 
corner, posterior corner, and anterolateral and postero-
lateral fat lesions all increased significantly during the 
52-week follow-up. Non-corner and facet joint fat lesions 
tended to increase, although this did not reach statistical 
significance. None of the components of the CANDEN 
MRI spine bone erosion score or the CANDEN MRI 
spine new bone formation score changed significantly 
during 52-week follow-up, although anterior corner and 
non-corner bone erosions tended to decrease slightly, 
and anterior and posterior corner new bone formation 
tended to increase slightly (see online supplementary 
table 3).
dIsCussIOn
The revised CANDEN MRI spine scoring system demon-
strated very good inter-reader agreement for the assess-
ment of inflammatory lesions and moderate to very good 
inter-reader agreement for the assessment of fat lesions 
for both status and change scores in this multireader 
study involving seven readers. The individual compo-
nents of these scores, whether from the vertebral bodies, 
that is, anterior corner, posterior corner and non-corner 
lesions, and anterolateral and posterolateral vertebral 
body lesions, or from the facet joints (for both inflam-
mation and fat), or from the transverse processes, ribs, 
spinous processes and soft tissue (for inflammation only), 
showed responsiveness to change. Inflammatory lesions 
decreased, while fat lesions increased during treatment, 
although for some components with a low frequency of 
lesions, change over time did not reach statistical signif-
icance. The proposed four subscores of spinal inflam-
mation, that is, the vertebral body corner inflammation 
subscore, the spondylodiscitis subscore, the facet joint 
inflammation subscore and the posterolateral elements 
inflammation subscore, all decreased significantly during 
follow-up in this cohort of patients treated with the TNF 
inhibitor golimumab.
The observed slight to moderate reliability for bone 
erosion and new bone formation status scores at baseline 
and their poor reliability for change over time may in 
part be explained by bone erosion and new bone forma-
tion being rather infrequent lesions in this cohort. The 
cohort consisted of biological treatment-naïve patients 
with axSpA, where many had only limited or no involve-
ment of the spine, and where little structural change 
happened during 52 weeks of follow-up. This length of 
follow-up may be too short a timeframe for detecting 
structural changes in patients with axSpA, but we were 
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able to identify a slight progression of new bone forma-
tion at the group level. When comparing the reliability for 
assessing spinal structural lesions across various studies, 
the proportion of patients who reached different stages 
in the evolution of disease should be taken into account. 
Higher reliability may be reached if patients were to be 
selected based on spinal involvement above a certain 
threshold at baseline, or in studies with longer follow-up 
since disease progression is slow. Another contributor to 
the slight to moderate reliability for bone erosion and 
new bone formation status scores is that structural lesions 
are often small and hard to detect on MRI T1-weighted 
images, where cortical bone provides no MRI signal and 
contrast and spatial resolution is limited compared with 
radiography. We have previously shown that the CANDEN 
MRI spine new bone formation score correlates with clin-
ical examination (Bath Ankylosing Spondylitis Metrology 
Index) as well as with a radiographic score (modified 
Stoke Ankylosing Spondylitis Spine Score, mSASSS).7 
Future studies may explore how well structural changes 
as assessed with MRI correlate with radiography or CT 
findings.
We have limited data on applying the CANDEN MRI 
spine scoring system to patients with severe involvement 
of the spine and with longer follow-up. A small longitu-
dinal study with serial lower spine MRI in patients with 
AS identified progression of CANDEN MRI spine fat 
score at 0.4 years of follow-up and CANDEN MRI spine 
new bone formation score at 0.8 years of follow-up at the 
group level, with additional progression in CANDEN 
MRI spine new bone formation also noted at up to 5 years 
of follow-up, whereas no change in CANDEN MRI spine 
bone erosion score was observed.8 This suggests that the 
CANDEN system can be used for monitoring structural 
MRI lesions of the spine in patients with axSpA at the 
group level. Further validation on the ability of the system 
to capture change in erosion and new bone formation 
across the entire spectrum of spondyloarthritis is needed.
Fat lesions and bone erosion of the facet joints have 
been added to the scoring system. The aim is to have a 
comprehensive scoring system. The image quality of MRI 
scans obtained today allows such lesions to be visualised, 
although in this cohort these lesion types were rare. An 
assessment of fat lesions and bone erosion in the facet 
joints also allows studies of development of ankylosis of 
the facet joints over time.
Lateral slices were tentatively assessed for bone 
erosion, but we decided not to include scoring of bone 
erosion on lateral slices in the scoring system. Not only 
in this read-out, but also in the overall experience of 
the group members, such lesions were considered infre-
quent, and it is inherently difficult or impossible to assess 
bone erosion and new bone formation at those locations 
confidently when only sagittal images are available due to 
partial volume artefacts. For the same reason, bone spurs 
and ankylosis are also scored only on central slices, not 
on lateral slices. It was decided to exclude non-corner 
erosion from the scoring system, since these lesions 
were also considered infrequent. Moreover, protrusion 
of nucleus pulposus through the vertebral endplate 
(Schmorl’s nodes), unrelated to spondyloarthritis, was 
judged to be a major confounder.
Inflammatory and fat lesions have been shown to 
predict radiographic progression at the same location on 
conventional spinal radiographs30 31; for the CANDEN 
MRI spine scoring system, this specifically pertains to 
anterior corner inflammatory lesions and anterior corner 
fat lesions.27–29 32 The value of the various MRI spine 
scores for predicting structural progression, for example, 
worsening in mSASSS, needs further clarification.
The CANDEN MRI spine scoring system may be used 
in its entirety, or parts of it may be used selectively, 
depending on the objectives of the study. In a randomised 
study with short follow-up time where the aim is to iden-
tify a between-group difference for change in spinal 
inflammation over time, it may be decided to only score 
inflammatory lesions. To keep scores comparable across 
studies, the terminology ‘CANDEN MRI spine inflamma-
tion score’, ‘CANDEN MRI spine fat score’, ‘CANDEN 
MRI spine bone erosion score’ and ‘CANDEN MRI spine 
new bone formation score’ should be used only when all 
components are scored and calculated as described in 
this article.
It may be considered a limitation of the scoring system 
that it is complex and requires a thorough training of 
readers as well as experience with musculoskeletal MRI. 
Not only the rules and definitions of the scoring system 
must be well understood, but the anatomy of the spine 
as visualised by MRI as well as the ability to identify the 
various lesion types seen in patients with spondyloarthritis 
must also be mastered. The system is not designed for use 
in daily clinical practice but is intended for research use.
Even though the scoring system is intended to be used 
in patients diagnosed with spondyloarthritis, such patients 
may also have concomitant degeneration of intervertebral 
discs and endplates with related bone marrow changes. 
We currently propose that in trials and observational 
cohorts of patients diagnosed with axSpA, all lesions that 
fulfil the definitions outlined here should be scored. The 
reader should not make a judgement whether a lesion 
is likely to be related to spondyloarthritis or not, but 
should decide whether the lesion fulfils the definitions 
provided. This gives a higher sensitivity for capturing all 
spinal lesions that are present, at the cost of a reduced 
diagnostic specificity from, for example, degeneration of 
intervertebral discs. Other ways of handling disc degen-
eration may be considered depending on the research 
design and the purpose of the study, for example, 
excluding scores from DVUs that are considered to have 
loss of at least 50% of normally expected disc height or 
where disc degeneration is obvious.33 The issue of degen-
erative spinal changes needs to be addressed in future 
studies to find a consistent handling of this major limita-
tion of any MRI spine assessment.
It is possible that some therapeutic interventions 
may vary in their impact on different components, for 
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example, entheseal inflammation in the vertebral bodies 
versus synovial joint inflammation in the facet joints. 
Using this scoring system, it is possible to calculate four 
inflammation subscores that may predominantly repre-
sent inflammation of different spinal structures, and 
which may respond differently to various treatments and 
may have different prognostic significance.
In conclusion, a comprehensive system for the evalu-
ation of inflammation, fat, bone erosion and new bone 
formation of the spine in patients with axSpA has been 
updated and validated. The system is designed for assess-
ment of the individual types of MRI lesions and for 
acquiring total scores for the different types of lesions 
(inflammation, fat, erosion and new bone formation). 
Moderate to very good reliability for the assessment of 
inflammatory lesions and fat lesions for both status scores 
and change scores and poor to moderate reliability for 
bone erosion and new bone formation status scores were 
demonstrated. The scoring system may be used to investi-
gate how drugs with different modes of action influence 
the individual components of MRI spine inflammation 
and damage, the mutual relationship between lesions, as 
well as the evolution of inflammation and damage in the 
entire spine.
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